Ally Bridge Group’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Ally Bridge Group’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-249,126	Closed	-$665K	–	22
2023 Q1	$665K	Sell	249,126 -619,277	-71%	-$2.4M	0.87%	18
2022 Q4	$3.12M	Hold	868,403	–	–	3.03%	14
2022 Q3	$5.59M	Buy	868,403 +531,913	+158%	+$4.32M	3.69%	11
2022 Q2	$3.24M	Hold	336,490	–	–	2.95%	15
2022 Q1	$4M	Sell	336,490 -17,500	-5%	-$313K	2.97%	15
2021 Q4	$11.5M	Buy	353,990 +10,000	+3%	+$405K	4.03%	9
2021 Q3	$15.4M	Hold	343,990	–	–	4.52%	8
2021 Q2	$18.7M	Buy	343,990 +30,000	+10%	+$1.78M	4.66%	6
2021 Q1	$23.5M	Buy	313,990 +49,740	+19%	+$5.17M	4.5%	5
2020 Q4	$28.7M	Buy	+264,250	New	+$24.1M	4.91%	6

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Ally Bridge Group's SYRS Position: Q2 2023 in Review

Ally Bridge Group sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2023, closing a stake of 249,126 shares — an estimated $665K sold.

Ally Bridge Group first reported a position in SYRS in Q4 2020 and held it in 10 quarters. The position peaked at $28.7M in Q4 2020. 53 funds tracked by Wall St. Rank hold SYRS as of Q2 2023.

Ally Bridge Group reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Ally Bridge Group sold 249,126 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $665K.
Ally Bridge Group first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 10 quarters.
Ally Bridge Group's Syros Pharmaceuticals, Inc. Common Stock position peaked at $28.7M in Q4 2020.
53 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Ally Bridge Group's 13F filing for Q2 2023, filed 14 Aug 2023.